Previous 10 | Next 10 |
Citi analyst Neena Bitritto-Garg says COMPASS Pathways (CMPS +2.9%) and Atai Life Sciences (ATAI +3.1%) are leading a revolution in psychedelic medicines. The pair backed by billionaires including Peter Thiel and German investor Christian Angermayer have dropped in value recently, as shown in...
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global...
NetworkNewsWire Editorial Coverage : There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want ...
Bad news for Apple and Amazon turned into good news for Microsoft (NASDAQ:MSFT) on Friday. While two of the software giant's megacap rivals suffered earnings-inspired declines, MSFT rose to a new 52-week high and took the crown as the world's largest company by market cap. Want to hear someth...
Oppenheimer has initiated COMPASS Pathways (CMPS +1.8%) with a buy, saying that the company's focus on psychoactive therapies for mental illness is leading a "psychedelic resurgence." The firm has a $50 price target on shares (~25% upside). Analyst Francois Brisebois says that it's "hard to o...
We are currently living through several simultaneous technology revolutions all of which are set to change everything about how we live our lives. The most important of them are encompassed by artificial intelligence, quantum computing, and advanced biotechnology, which now includes ide...
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing their go-to-market strategy. The market players of psychedel...
If you've ever been depressed, you know how difficult it can be to get a leg up on getting back to a sound state of mind. To help people suffering from depression and other mental illnesses, Compass Pathways (NASDAQ: CMPS) makes psychedelic therapies based on chemicals like psilocyb...
“Magic mushrooms may be the biggest advance in treating depression since Prozac,” says Newsweek. Not only has the US FDA granted “breakthrough status” to psilocybin, dozens of medical studies are seeing positive study results, including Johns Hopkins Medicine and...
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evide...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...